Skip to main content
SpringerLink
Log in

Management of BPH and LUTS

  • Chapter
  • First Online:
Design and Implementation of the Modern Men’s Health Center

  • 347 Accesses

Abstract

Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) are highly prevalent in the general population and are a crucial component in the evaluation of male patients in the primary care setting. The etiology and pathophysiology can be quite complex. Initial treatment of BPH/LUTS has shifted from primary surgical therapy to medical treatment with the advent of many novel therapeutics. With the proper background knowledge, primary care providers can be actively involved in the management of patients with BPH/LUTS. After consideration of the differential diagnosis, primary care providers can initiate treatment for patients and continue to monitor patients for improvement. There are useful tools that providers can use to objectively measure the degree of symptoms and whether patients are responding to treatment. When medical management fails, urologists can provide advanced management and surgical intervention. Through the use of many new and innovative technologies, urologists are able provide treatment for patients in a minimally invasive fashion.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Bibliography

  1. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43(3):289–97.

    Article  PubMed  Google Scholar 

  2. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545–57.

    Article  CAS  PubMed  Google Scholar 

  3. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(4):1323–8.

    Article  CAS  PubMed  Google Scholar 

  4. Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J Urol. 2010;184(3):1040–4.

    Article  CAS  PubMed  Google Scholar 

  5. McNeal JE. Origin and evolution of benign prostatic enlargement. Investig Urol. 1978;15(4):340–5.

    CAS  Google Scholar 

  6. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am. 2011;95(1):87–100.

    Article  PubMed  Google Scholar 

  7. Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19(5):609–29.

    Article  CAS  PubMed  Google Scholar 

  8. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979;121(5):640–2.

    Article  CAS  PubMed  Google Scholar 

  9. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.

    Article  CAS  PubMed  Google Scholar 

  10. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol. 1997;4(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  11. Nacey JN, Morum P, Delahunt B. Analysis of the prevalence of voiding symptoms in Maori, Pacific Island, and Caucasian New Zealand men. Urology. 1995;46(4):506–11.

    Article  CAS  PubMed  Google Scholar 

  12. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE, et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology. 1994;44(6):825–31.

    Article  CAS  PubMed  Google Scholar 

  13. Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, et al. Lower urinary tract symptoms, prostate volume and uroflow in norwegian community men. Eur Urol. 2001;39(1):36–41.

    Article  CAS  PubMed  Google Scholar 

  14. Bosch JL, Hop WC, Niemer AQ, Bangma CH, Kirkels WJ, Schroder FH. Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol. 1994;152(5 Pt 1):1501–5.

    Article  CAS  PubMed  Google Scholar 

  15. Djavan B, Fong YK, Harik M, Milani S, Reissigl A, Chaudry A, et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004;64(6):1144–8.

    Article  PubMed  Google Scholar 

  16. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

    Article  CAS  PubMed  Google Scholar 

  17. Grosse H. Frequency, localization and associated disorders in urinary calculi. Analysis of 1671 autopsies in urolithiasis. Z Urol Nephrol. 1990;83(9):469–74.

    CAS  PubMed  Google Scholar 

  18. Hunter DJ, Berra-Unamuno A, Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol. 1996;155(6):1965–70.

    Article  CAS  PubMed  Google Scholar 

  19. Kim JW, Oh MM, Park HS, Cheon J, Lee JG, Kim JJ, et al. Intravesical prostatic protrusion is a risk factor for bladder stone in patients with benign prostatic hyperplasia. Urology. 2014;84(5):1026–9.

    Article  PubMed  Google Scholar 

  20. Gosling JA, Dixon JS. Structure of trabeculated detrusor smooth muscle in cases of prostatic hypertrophy. Urol Int. 1980;35(5):351–5.

    Article  CAS  PubMed  Google Scholar 

  21. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(Suppl 9):S3–s10.

    PubMed  PubMed Central  Google Scholar 

  22. Fusco F, Creta M, De Nunzio C, Iacovelli V, Mangiapia F, Li Marzi V, et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018;18(1):15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guide Quick Ref Guide Clin. 1994;8:1–17.

    Google Scholar 

  24. Heyns CF. Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder. World J Urol. 2012;30(1):77–83.

    Article  CAS  PubMed  Google Scholar 

  25. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, Proctor C. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol. 1989;141(2):248–53.

    Article  CAS  PubMed  Google Scholar 

  26. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals follow-up study. J Urol. 1999;162(2):376–82.

    Article  CAS  PubMed  Google Scholar 

  27. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(9):481–7.

    CAS  PubMed  Google Scholar 

  28. Mukamel E, Nissenkorn I, Boner G, Servadio C. Occult progressive renal damage in the elderly male due to benign prostatic hypertrophy. J Am Geriatr Soc. 1979;27(9):403–6.

    Article  CAS  PubMed  Google Scholar 

  29. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995;332(2):75–9.

    Article  CAS  PubMed  Google Scholar 

  30. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl. 2001;22(3):432–43.

    CAS  PubMed  Google Scholar 

  31. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169(1):20–3.

    Article  CAS  PubMed  Google Scholar 

  32. Bruha M, Welliver C. Is there a role for preoperative 5 alpha reductase inhibitors in reducing prostate vascularity and blood loss? Curr Urol Rep. 2017;18(10):75.

    Article  PubMed  Google Scholar 

  33. Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13.

    Article  PubMed  Google Scholar 

  34. Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol. 2011;13(1):20–33.

    PubMed  PubMed Central  Google Scholar 

  35. Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol. 1993;150(6):2002–6.

    Article  CAS  PubMed  Google Scholar 

  36. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am. 1995;22(2):375–86.

    Article  CAS  PubMed  Google Scholar 

  37. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl 4):S3–9.

    PubMed  PubMed Central  Google Scholar 

  38. Srinivasan S, Radomski S, Chung J, Plazker T, Singer S, Slomovic AR. Intraoperative floppy-iris syndrome during cataract surgery in men using alpha-blockers for benign prostatic hypertrophy. J Cataract Refract Surg. 2007;33(10):1826–7.

    Article  PubMed  Google Scholar 

  39. Chadha V, Borooah S, Tey A, Styles C, Singh J. Floppy iris behaviour during cataract surgery: associations and variations. Br J Ophthalmol. 2007;91(1):40–2.

    Article  CAS  PubMed  Google Scholar 

  40. Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. Curr Opin Ophthalmol. 2009;20(1):37–41.

    Article  PubMed  Google Scholar 

  41. Amin K, Fong K, Horgan SE. Incidence of intra-operative floppy iris syndrome in a U.K. district general hospital and implications for future workload. Surg. 2008;6(4):207–9.

    CAS  Google Scholar 

  42. Bell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Gruneir A, et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA. 2009;301(19):1991–6.

    Article  CAS  PubMed  Google Scholar 

  43. Blouin MC, Blouin J, Perreault S, Lapointe A, Dragomir A. Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. J Cataract Refract Surg. 2007;33(7):1227–34.

    Article  PubMed  Google Scholar 

  44. Cantrell MA, Bream-Rouwenhorst HR, Steffensmeier A, Hemerson P, Rogers M, Stamper B. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother. 2008;42(4):558–63.

    Article  CAS  PubMed  Google Scholar 

  45. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664–73.

    Article  PubMed  Google Scholar 

  46. Chang DF, Osher RH, Wang L, Koch DD. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology. 2007;114(5):957–64.

    Article  PubMed  Google Scholar 

  47. Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2006;32(8):1336–9.

    Article  PubMed  Google Scholar 

  48. Keklikci U, Isen K, Unlu K, Celik Y, Karahan M. Incidence, clinical findings and management of intraoperative floppy iris syndrome associated with tamsulosin. Acta Ophthalmol. 2009;87(3):306–9.

    Article  PubMed  Google Scholar 

  49. Oshika T, Ohashi Y, Inamura M, Ohki K, Okamoto S, Koyama T, et al. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. Am J Ophthalmol. 2007;143(1):150–1.

    Article  PubMed  Google Scholar 

  50. Takmaz T, Can I. Clinical features, complications, and incidence of intraoperative floppy iris syndrome in patients taking tamsulosin. Eur J Ophthalmol. 2007;17(6):909–13.

    Article  CAS  PubMed  Google Scholar 

  51. McVary KT, Roehrborn CG, Avins Al, Barry MJ, Bruskewitz RC, Donell RF, et al. Update on AUA guidline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–03.

    Google Scholar 

  52. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399–403.

    Article  CAS  PubMed  Google Scholar 

  53. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84.

    Article  CAS  PubMed  Google Scholar 

  54. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74(3):505–8.

    CAS  PubMed  Google Scholar 

  55. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10(2):149–54.

    Article  CAS  PubMed  Google Scholar 

  56. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533–9.

    Article  CAS  PubMed  Google Scholar 

  57. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119–26.

    Article  PubMed  Google Scholar 

  58. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.

    Article  CAS  PubMed  Google Scholar 

  59. Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-alpha-reductase inhibitors finasteride and dutasteride: a comprehensive review. Dermatol Online. J. 2017;23(11).

    Google Scholar 

  60. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.

    Article  CAS  PubMed  Google Scholar 

  61. Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, et al. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PLoS One. 2015;10(5):e0126672.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M. Risk of prostate cancer in men treated with 5alpha-reductase inhibitors-a large population-based prospective study. J Natl Cancer Inst. 2018;110:1216–21.

    Article  PubMed  Google Scholar 

  63. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177(3):1071–7.

    Article  CAS  PubMed  Google Scholar 

  64. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180(4):1228–34.

    Article  CAS  PubMed  Google Scholar 

  65. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53(6):1236–44.

    Article  CAS  PubMed  Google Scholar 

  66. Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology. 2011;77(1):123–9.

    Article  PubMed  Google Scholar 

  67. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology. 1995;45(3):440–6.

    Article  CAS  PubMed  Google Scholar 

  68. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49.

    Article  PubMed  Google Scholar 

  69. Huang SA, Lie JD. Phosphodiesterase-5 (PDE(5)) inhibitors in the management of erectile dysfunction. Pharm Therap. 2013;38(7):407–19.

    Google Scholar 

  70. Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279–90.

    CAS  PubMed  Google Scholar 

  71. Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018;189:130–48.

    Article  CAS  PubMed  Google Scholar 

  72. Staskin DR, Zoltan E. Anticholinergics and central nervous system effects: are we confused? Rev Urol. 2007;9(4):191–6.

    PubMed  PubMed Central  Google Scholar 

  73. Lose G, Lalos O, Freeman RM, van Kerrebroeck P. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol. 2003;189(4):1106–13.

    Article  CAS  PubMed  Google Scholar 

  74. Kaminetsky J, Wein A, Dmochowski R, Herschkowitz S, Cheng M, Abrams S, et al. MP74-01 A randomized, double-blind, placebo controlled study of 2 doses of SER120 (low dose desmopressin) nasal spray in patients with nocturia. J Urol. 2016;195(4):e969.

    Google Scholar 

  75. Weiss JP, Herschorn S, Albei CD, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190(3):965–72.

    Article  CAS  PubMed  Google Scholar 

  76. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006;50(5):969–79; discussion 80.

    Article  PubMed  Google Scholar 

  77. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246–9.

    Article  PubMed  Google Scholar 

  78. Ekengren J, Haendler L, Hahn RG. Clinical outcome 1 year after transurethral vaporization and resection of the prostate. Urology. 2000;55(2):231–5.

    Article  CAS  PubMed  Google Scholar 

  79. Hammadeh MY, Madaan S, Singh M, Philp T. A 3-year follow-up of a prospective randomized trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomy. BJU Int. 2000;86(6):648–51.

    Article  CAS  PubMed  Google Scholar 

  80. Mordasini L, Di Bona C, Klein J, Mattei A, Wirth GJ, Iselin CE. 80-W GreenLight laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic obstruction: 5-year outcomes of a single-center prospective randomized trial. Urology. 2018;116:144–9.

    Article  PubMed  Google Scholar 

  81. Brunken C, Seitz C, Woo HH. A systematic review of experience of 180-W XPS GreenLight laser vaporisation of the prostate in 1640 men. BJU Int. 2015;116(4):531–7.

    Article  PubMed  Google Scholar 

  82. Lukacs B, Loeffler J, Bruyere F, Blanchet P, Gelet A, Coloby P, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol. 2012;61(6):1165–73.

    Article  PubMed  Google Scholar 

  83. Michalak J, Tzou D, Funk J. HoLEP: the gold standard for the surgical management of BPH in the 21(st) century. Am J Clin Exp Urol. 2015;3(1):36–42.

    PubMed  PubMed Central  Google Scholar 

  84. Kuo RL, Paterson RF, Kim SC, Siqueira TM Jr, Elhilali MM, Lingeman JE. Holmium laser enucleation of the prostate (HoLEP): a technical update. World J Surg Oncol. 2003;1:6.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Aagaard MF, Niebuhr MH, Jacobsen JD, Kroyer Nielsen K. Transurethral microwave thermotherapy treatment of chronic urinary retention in patients unsuitable for surgery. Scand J Urol. 2014;48(3):290-4. 2168–1813 (Electronic).

    Google Scholar 

  86. Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, Wilt TJ, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;(9):CD004135. 1469–493X (Electronic).

    Google Scholar 

  87. Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum((R)) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:13–8.

    PubMed  PubMed Central  Google Scholar 

  88. Helo S, Holland B, McVary KT. Convective radiofrequency water vapor thermal therapy with Rezum system. Curr Urol Rep. 2017;18(10):78.

    Article  PubMed  Google Scholar 

  89. Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042–7.

    Article  PubMed  Google Scholar 

  90. McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–38.

    Article  PubMed  Google Scholar 

  91. McVary K, Mynderse L, Gange S, Gittelman M, Goldberg K, Patel K, et al. PII-LBA1 using the thermal energy of convectively delivered water vapor for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: the rezum II study. J Urol. 2015;193(4):e495.

    Google Scholar 

  92. Gupta N, Rogers T, Holland B, Helo S, Dynda D, McVary KT. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol. 2018;200:405–13.

    Article  CAS  PubMed  Google Scholar 

  93. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation – image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117(6):923–9.

    Article  CAS  PubMed  Google Scholar 

  94. Yassaie O, Silverman JA, Gilling PJ. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: early results. Curr Urol Rep. 2017;18(12):91.

    Article  PubMed  Google Scholar 

  95. Kasivisvanathan V, Hussain M. Aquablation versus transurethral resection of the prostate: 1 year United States – cohort outcomes. Can J Urol. 2018;25(3):9317–22.

    PubMed  Google Scholar 

  96. Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2161–7.

    Article  PubMed  Google Scholar 

  97. Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P. Prostatic urethral lift: does size matter? J Endourol. 2018;32(7):635–8.

    Article  PubMed  Google Scholar 

  98. Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015;68(4):643–52.

    Article  PubMed  Google Scholar 

  99. Larcher A, Broglia L, Lughezzani G, Mistretta F, Abrate A, Lista G, et al. Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature. Curr Urol Rep. 2013;14(6):620–7.

    Article  PubMed  Google Scholar 

  100. Ferretti M, Phillips J. Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. Can J Urol. 2015;22 Suppl 1:60–6.

    PubMed  Google Scholar 

  101. Adam C, Hofstetter A, Deubner J, Zaak D, Weitkunat R, Seitz M, et al. Retropubic transvesical prostatectomy for significant prostatic enlargement must remain a standard part of urology training. Scand J Urol Nephrol. 2004;38(6):472–6.

    Article  PubMed  Google Scholar 

  102. Condie JD Jr, Cutherell L, Mian A. Suprapubic prostatectomy for benign prostatic hyperplasia in rural Asia: 200 consecutive cases. Urology. 1999;54(6):1012–6.

    Article  PubMed  Google Scholar 

  103. Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int. 2003;91(3):196–200.

    Article  CAS  PubMed  Google Scholar 

  104. Gratzke C, Schlenker B, Seitz M, Karl A, Hermanek P, Lack N, et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol. 2007;177(4):1419–22.

    Article  PubMed  Google Scholar 

  105. Helfand B, Mouli S, Dedhia R, McVary KT. Management of lower urinary tract symptoms secondary to benign prostatic hyperplasia with open prostatectomy: results of a contemporary series. J Urol. 2006;176(6 Pt 1):2557–61; discussion 61.

    Article  PubMed  Google Scholar 

  106. Serretta V, Morgia G, Fondacaro L, Curto G, Lo bianco A, Pirritano D, et al. Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. Urology. 2002;60(4):623–7.

    Article  PubMed  Google Scholar 

  107. Shaheen A, Quinlan D. Feasibility of open simple prostatectomy with early vascular control. BJU Int. 2004;93(3):349–52.

    Article  CAS  PubMed  Google Scholar 

  108. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol. 2001;166(1):172–6.

    Article  CAS  PubMed  Google Scholar 

  109. Varkarakis I, Kyriakakis Z, Delis A, Protogerou V, Deliveliotis C. Long-term results of open transvesical prostatectomy from a contemporary series of patients. Urology. 2004;64(2):306–10.

    Article  PubMed  Google Scholar 

  110. Li Z, Chen P, Wang J, Mao Q, Xiang H, Wang X, et al. The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: a systematic review and network meta-analysis. Medicine. 2016;95(24):e3862.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Sorokin I, Sundaram V, Singla N, Walker J, Margulis V, Roehrborn C, et al. Robot-assisted versus open simple prostatectomy for benign prostatic hyperplasia in large glands: a propensity score-matched comparison of perioperative and short-term outcomes. J Endourol. 2017;31(11):1164–9.

    Article  PubMed  Google Scholar 

  112. Holden M, Parsons JK. Robotic-assisted simple prostatectomy: an overview. Urol Clin North Am. 2016;4(3):385–91.

    Article  Google Scholar 

  113. Hill AG, Njoroge P. Suprapubic transvesical prostatectomy in a rural Kenyan hospital. East Afr Med J. 2002;79(2):65–7.

    Article  CAS  PubMed  Google Scholar 

  114. Chiou RK, Chen WS, Akbari A, Foley S, Lynch B, Taylor RJ. Long-term outcome of prostatic stent treatment for benign prostatic hyperplasia. Urology. 1996;48(4):589–93.

    Article  CAS  PubMed  Google Scholar 

  115. Sethi K, Bozin M, Jabane T, McMullin R, Cook D, Forsyth R, et al. Thermo-expandable prostatic stents for bladder outlet obstruction in the frail and elderly population: an underutilized procedure? Investig Clin Urol. 2017;58(6):447–52.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Skydsgaard Schou-Jensen K, Dahl C, Azawi NH. Prostate stent is an option for selected patients who are unsuitable for transurethral resection of the prostate. Dan Med J. 2014;61(10):A4937.

    PubMed  Google Scholar 

  117. McWilliams JP, Kuo MD, Rose SC, Bagla S, Caplin DM, Cohen EI, et al. Society of Interventional Radiology position statement: prostate artery embolization for treatment of benign disease of the prostate. J Vasc Interv Radiol. 2014;25(9):1349–51.

    Article  PubMed  Google Scholar 

  118. Teichgraber U, Aschenbach R, Diamantis I, von Rundstedt FC, Grimm MO, Franiel T. Prostate artery embolization: indication, technique and clinical results. RoFo. 2018;190(9):847–55.

    Article  PubMed  Google Scholar 

  119. Gao YA, Huang Y, Zhang R, Yang YD, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate--a prospective, randomized, and controlled clinical trial. Radiology. 2014;270(3):920–8.

    Article  PubMed  Google Scholar 

  120. Petrillo M, Pesapane F, Fumarola EM, Emili I, Acquasanta M, Patella F, et al. State of the art of prostatic arterial embolization for benign prostatic hyperplasia. Gland Surg. 2018;7(2):188–99.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Maclean D, Maher B, Modi S, Harris M, Dyer J, Somani B, et al. Prostate artery embolization: a new, minimally invasive treatment for lower urinary tract symptoms secondary to prostate enlargement. Ther Adv Urol. 2017;9(8):209–16.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NYU, Department of Urology, New York, NY, USA

    Benjamin Brucker, Matthew Katz & Michael Siev

Authors
  1. Benjamin Brucker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Siev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Brucker .

Editor information

Editors and Affiliations

  1. Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA

    Joseph P. Alukal

  2. Preston Robert Tisch Center, New York University, New York, NY, USA

    Steven Lamm

  3. University of Washington, Seattle, WA, USA

    Thomas J. Walsh

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brucker, B., Katz, M., Siev, M. (2021). Management of BPH and LUTS. In: Alukal, J.P., Lamm, S., Walsh, T.J. (eds) Design and Implementation of the Modern Men’s Health Center. Springer, Cham. https://doi.org/10.1007/978-3-030-54482-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54482-9_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54481-2

  • Online ISBN: 978-3-030-54482-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation